二重特異性抗体市場：作用機序、治療領域、エンドユーザー別-2025-2030年の世界予測

二重特異性抗体市場は、2023年に57億1,000万米ドルと評価され、2024年にはCAGR 32.64%で74億9,000万米ドルに成長し、2030年には412億9,000万米ドルに達すると予測されています。

二重特異性抗体は画期的な治療法として急速に台頭しており、複数の疾患領域において治療パラダイムの再定義を行っています。精度と標的を絞った介入が最重要視される今日の環境において、この革新的な薬剤は生物医学の最前線に立っています。2つの異なる抗原に同時に作用する抗体の設計を支える科学は大幅に進歩し、従来の治療法に比べて優れた特異性と効力を発揮しています。本レポートでは、二重特異性抗体市場を詳細に分析し、市場促進要因、技術的ブレークスルー、進化する市場戦略を探る。臨床的な進歩と基礎となる分子メカニズムの両方を検証することで、二重特異性抗体の治療の可能性を現代医学の幅広い文脈の中に位置づけています。意思決定に影響を与える戦略的・経営的側面に焦点を当て、このダイナミックなセグメントの影響と将来の軌道を理解しようとする業界の専門家や主要な意思決定者向けに編集されています。この包括的な調査により、二特異性抗体は、多様な治療用途において、その治療戦略を再構築する上で計り知れない価値があり、市場において影響力を増していることが明らかになりました。

二重特異性抗体市場の変革

二特異性抗体市場は、臨床戦略と商業戦略の両方を再構築する重要な進歩に牽引され、変革期を迎えています。技術革新はこれらの複雑な分子の発見と最適化を加速し、最終的には洗練された分子工学によって標的抗原とのエンゲージメントを高めることを可能にしました。規制当局のアプローチも進化しており、迅速な上市への道筋と、高水準を維持するための厳格な安全性評価とのバランスをとっています。このようなシフトは、製薬企業とバイオテクノロジー・イノベーターとの戦略的提携によってさらに強化され、臨床試験とベンチからベッドサイドへの移行を加速させる競争的でありながら共生的なエコシステムを育んでいます。適応性のある臨床デザインと強固なデータ解析への投資により、重要な有効性と安全性のプロファイルが明らかになり、企業は患者選択を洗練させ、治療成果を最大化することが可能になりました。この進化する情勢は、科学的発見、規制状況の進展、市場適応の間のダイナミックな相互作用によって特徴付けられ、利害関係者が急速に変化する環境において、常に情報を入手し、機敏に行動する必要性を強調しています。このような変革的なシフトを活用することで、業界のリーダーたちは、二重特異性抗体の可能性を最大限に活用し、有意義な臨床的進歩を推進することができます。

主要なセグメンテーションの洞察

詳細なセグメンテーション分析により、二重特異性抗体市場をより深く理解し、標的介入の道を明らかにし、成長機会を明らかにします。作用機序に基づく市場調査では、二重抗原ターゲティング、二重阻害抗体、T細胞エンゲイジャーなどのアプローチが、治療効果や市場ダイナミクスを形成する上で極めて重要な役割を果たしていることが明らかになりました。これと並行して、治療領域に基づくセグメンテーションにより、自己免疫疾患や感染症から神経疾患や腫瘍に至るまで、幅広い疾患が臨床応用の要となっていることが明らかになりました。この多面的なアプローチにより、利害関係者は、アンメットニーズが最も高く、潜在的な収益源が新たな臨床エビデンスと最適に整合するセグメントをピンポイントで特定することができます。さらに、エンドユーザーのセグメンテーションでは、病院や専門クリニックでのアプリケーションと、研究機関や学術センターで追求されるアプリケーションを区別することで、市場の展望を明確にしています。これらの相互関連的な視点は、市場ターゲットを絞り込むだけでなく、患者中心のニーズ、臨床需要、治療手法の全体的な進化をより深く理解することにもつながります。こうしたセグメンテーションの変数を認識することは、強靭なポートフォリオを構築し、効果的な市場参入戦略を実施しようとする戦略家にとって不可欠です。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に感染症や慢性疾患の発生率が上昇
    • 遺伝子工学およびタンパク質工学技術の進歩
    • 新規二重特異性抗体の開発と承認に対する規制当局の支援の拡大
  • 抑制要因
    • 二重特異性抗体の製造における複雑さ
  • 機会
    • 個別化治療アプローチへの新たなトレンド
    • 希少疾患治療における二重特異性抗体の利用拡大
  • 課題
    • 二重特異性抗体の安全性と有効性に関する問題
• 市場セグメンテーション分析
  • 作用機序：オフターゲット効果を最小限に抑えるための二重抗原標的化の優先度の増加
  • 治療領域：がん細胞を捕捉し破壊するための腫瘍学における二重特異性抗体の応用拡大
  • エンドユーザー：病院や専門クリニックにおける包括的な治療ケアの提供
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 二重特異性抗体市場作用機序別

• 二重抗原標的
• 二重ブロッキング抗体
• T細胞エンゲージャー

第7章 二重特異性抗体市場治療領域別

• 自己免疫疾患
• 感染症
• 神経疾患
• 腫瘍学

第8章 二重特異性抗体市場：エンドユーザー別

• 病院と専門クリニック
• 調査機関および学術センター

第9章 南北アメリカの二重特異性抗体市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の二重特異性抗体市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの二重特異性抗体市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adimab, LLC
• Affimed GmbH
• Alligator Bioscience AB
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb
• Eli Lilly and Company
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche Ltd.
• Genmab A/S
• Gilead Sciences, Inc.
• Innovent Biologics, Inc.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Mereo Biopharma Group PLC
• Merus N.V.
• Novartis AG
• Pfizer Inc.
• Pieris Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• TG Therapeutics, Inc.
• Xencor, Inc.

LIST OF FIGURES

• FIGURE 1. BISPECIFIC ANTIBODIES MARKET MULTI-CURRENCY
• FIGURE 2. BISPECIFIC ANTIBODIES MARKET MULTI-LANGUAGE
• FIGURE 3. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
• FIGURE 4. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
• TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 31. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 48. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 51. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 103. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 115. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 118. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

The Bispecific Antibodies Market was valued at USD 5.71 billion in 2023 and is projected to grow to USD 7.49 billion in 2024, with a CAGR of 32.64%, reaching USD 41.29 billion by 2030.

Bispecific antibodies are rapidly emerging as groundbreaking therapeutic modalities, redefining treatment paradigms across multiple disease areas. In today's environment, where precision and targeted intervention are paramount, these innovative agents stand at the forefront of biomedical science. The science behind designing antibodies that can engage two different antigens simultaneously has advanced considerably, providing superior specificity and potency compared to traditional therapies. This report offers an in-depth analysis of the bispecific antibody market, exploring critical drivers, technological breakthroughs, and evolving market strategies. By examining both clinical advancements and underlying molecular mechanisms, the narrative places the therapeutic potential of bispecific antibodies in a broader context of modern medicine. With a focus on the strategic and operational aspects that influence decision-making, the discussion is tailored for industry experts and key decision-makers looking to understand the impact and future trajectory of this dynamic segment. This comprehensive exploration underscores the immense value and growing market influence of bispecific antibodies in reshaping treatment landscapes across a diverse array of therapeutic applications.

Transformative Shifts in the Landscape

The bispecific antibodies market is undergoing a transformative shift driven by significant advancements that are reshaping both clinical and commercial strategies. Technological innovations have accelerated the discovery and optimization of these complex molecules, ultimately allowing for enhanced engagement with target antigens through refined molecular engineering. Regulatory agencies have also evolved in their approach, balancing expedited pathways to market with stringent safety evaluations to maintain high standards. These shifts are further bolstered by strategic collaborations between pharmaceutical companies and biotechnology innovators, fostering a competitive yet symbiotic ecosystem that accelerates clinical trials and bench-to-bedside transitions. Investment in adaptive clinical design and robust data analytics has illuminated critical efficacy and safety profiles, making it possible for companies to refine patient selection and maximize therapeutic outcomes. This evolving landscape is characterized by the dynamic interplay between scientific discovery, regulatory progression, and market adaptation, underscoring the necessity for stakeholders to remain informed and agile in a rapidly changing environment. By leveraging these transformative shifts, industry leaders are uniquely positioned to harness the full potential of bispecific antibodies and drive meaningful clinical advancements.

Key Segmentation Insights

A detailed segmentation analysis provides a nuanced understanding of the bispecific antibodies market, clarifying avenues for targeted intervention and highlighting growth opportunities. When studying the market based on the mechanism of action, it becomes clear that approaches such as dual antigen targeting, dual-blocking antibodies, and T-cell engagers play pivotal roles in shaping therapeutic efficacy and market dynamics. In parallel, segmentation based on therapeutic area reveals that conditions ranging from autoimmune diseases and infectious diseases to neurological disorders and oncology form the cornerstone of clinical application. This multifaceted approach allows stakeholders to pinpoint segments where unmet needs are highest and potential revenue streams are optimally aligned with emerging clinical evidence. Furthermore, the end-user segmentation delineates the market landscape by distinguishing applications within hospitals and specialist clinics from those pursued in research institutions and academic centers. These interconnected perspectives not only refine market targeting but also foster a deeper understanding of patient-centric needs, clinical demands, and the overall evolution of treatment methodologies. Recognizing these segmentation variables is essential for strategists looking to create a resilient portfolio and implement effective market entry strategies.

Based on Mechanism of Action, market is studied across Dual Antigen Targeting, Dual-Blocking Antibodies, and T-cell Engagers.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Infectious Diseases, Neurological Disorders, and Oncology.

Based on End-user, market is studied across Hospitals & Specialist Clinics and Research Institutions & Academic Centers.

Key Regional Insights

Geographic dynamics play a crucial role in determining market trends and resource allocation in the bispecific antibodies domain. In-depth analysis across various regions reveals distinctive characteristics that influence both product development and adoption rates. The Americas showcase robust infrastructure with thriving biopharmaceutical networks and advanced clinical research facilities that have propelled rapid commercialization. Meanwhile, regions such as Europe, the Middle East, and Africa are witnessing steady growth, supported by comprehensive regulatory reforms and strategic public-private partnerships fostering increased investment in innovative therapies. The Asia-Pacific region, with its burgeoning markets and escalating levels of healthcare expenditure, represents a frontier of potential, driving a surge in clinical research initiatives and collaborative ventures. The integration of region-specific insights with overarching market analysis underscores the importance of tailoring strategies to local nuances while leveraging global industry trends. These regional differentiators not only create diverse investment opportunities but also encourage harmonized regulatory landscapes and drive the broader acceptance of bispecific antibody technologies across varied demographic and economic settings.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, Michigan, Montana, New York, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The bispecific antibodies market is characterized by the active participation of a range of influential companies, each contributing unique technological capabilities and strategic direction. Industry leaders such as AbbVie Inc., Adimab, LLC, and Affimed GmbH continue to drive innovation through focused research and robust clinical development programs. Companies like Alligator Bioscience AB and Amgen Inc. have advanced their portfolios by capitalizing on novel therapeutic modalities to address unmet medical needs. Other major players, including Astellas Pharma Inc. and AstraZeneca PLC, have integrated bispecific approaches into comprehensive treatment strategies, further complemented by the expertise of Bristol-Myers Squibb and Eli Lilly and Company. Notable contributions from Emergent BioSolutions Inc. and F. Hoffmann-La Roche Ltd. have provided clarity in regulatory pathways and clinical trial design, while Genmab A/S and Gilead Sciences, Inc. have leveraged synergistic partnerships to accelerate drug development. Innovent Biologics, Inc., Johnson & Johnson Services, Inc., and Merck KGaA continue to shape the competitive landscape with robust research pipelines. Other recognized companies such as Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc. bring valuable insights and diversified strategies, collectively reinforcing the market's innovation ecosystem.

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Alligator Bioscience AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are urged to harness the transformative trends within the bispecific antibodies market by integrating strategic, research-driven, and patient-focused approaches into their core business models. A comprehensive review of existing portfolios is critical, with companies encouraged to invest in state-of-the-art technologies that facilitate rapid candidate screening and reliable efficacy assessments. Capitalizing on cross-disciplinary partnerships can expedite the translation of novel research findings into clinical applications, thereby bridging the gap between innovation and market readiness. Leaders should also pay careful attention to evolving regulatory frameworks and invest in building agile compliance systems that enable swift adjustments to new guidelines. It is imperative to align R&D strategies with insights derived from detailed segmentation analyses, ensuring that therapeutic development is both targeted and adaptive. Dedicated initiatives to nurture talent in emerging fields, coupled with an emphasis on robust clinical trial designs, can further strengthen a company's market positioning. By adopting these actionable recommendations, decision-makers can not only mitigate risks but also drive sustainable growth, fortifying their competitive edge in a rapidly advancing therapeutic landscape.

Conclusion: Charting the Future of Bispecific Antibodies

In summary, the bispecific antibodies market is at a pivotal juncture, where rapid technological advances meet unmet clinical needs. The extensive segmentation analysis, coupled with evolving regional trends and significant contributions from leading companies, paints a comprehensive picture of a dynamic and promising therapeutic landscape. With transformative shifts in market paradigms and a clear delineation of strategic opportunities, stakeholders are well-positioned to propel innovation and optimize patient outcomes. The interplay between science, regulatory action, and market dynamics creates a fertile ground for sustained growth and renewed confidence from investors and clinicians alike. As companies fine-tune their strategies to harness these emerging opportunities, the future of bispecific antibodies looks set to redefine conventional treatment methodologies and offer unprecedented clinical benefits. This conclusion not only celebrates current achievements but also serves as a clarion call for further research, investment, and strategic alignment in this fast-evolving market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of infectious and chronic illnesses globally
    • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
    • 5.1.1.3. Growing regulatory support for the development and approval of novel bispecific antibodies
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in the manufacturing of bispecific antibodies
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging trend toward personalized therapeutic approaches
    • 5.1.3.2. Expanding usage of bispecific antibodies in the treatment of rare diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Issues associated with the safety and efficacy of bispecific antibodies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
  • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
  • 5.2.3. End-user: Provision of comprehensive therapeutic care in hospitals and specialist clinics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bispecific Antibodies Market, by Mechanism of Action

• 6.1. Introduction
• 6.2. Dual Antigen Targeting
• 6.3. Dual-Blocking Antibodies
• 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Autoimmune Diseases
• 7.3. Infectious Diseases
• 7.4. Neurological Disorders
• 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

• 8.1. Introduction
• 8.2. Hospitals & Specialist Clinics
• 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Merck & Co Inc expands oncology portfolio with acquisition of novel bispecific antibody for B-cell malignancies
  • 12.3.2. Novartis collaborates with Dren Bio, for innovative bispecific antibodies to revolutionize cancer treatments
  • 12.3.3. Johnson & Johnson's Acquisition of Numab Therapeutics Boosting Bispecific Antibody Pipeline
  • 12.3.4. Regeneron highlights promising anti-tumor activity of novel bispecific antibody REGN7075
  • 12.3.5. Zenas Biopharma raises USD 200 Million in Series C Funding
  • 12.3.6. Invenra and Astellas Pharma form strategic partnership to enhance bispecific antibody R&D using the B-Body platform
  • 12.3.7. Biotheus and Hansoh Pharma expand partnership to develop innovative bispecific antibody-drug conjugates for cancer treatment
  • 12.3.8. FDA approves Johnson & Johnson's TECVAYLI for biweekly dosing in multiple myeloma
  • 12.3.9. AstraZeneca advances cancer treatment with innovative bispecific antibodies targeting multiple tumor antigens
  • 12.3.10. Janssen's TALVEY talquetamab-tgvs receives FDA accelerated approval
  • 12.3.11. FDA greenlights AbbVie and Genmab's EPKINLY for relapsed or refractory DLBCL
  • 12.3.12. Pfizer's elranatamab receives priority review by US FDA and EMA with positive trial results
• 12.4. Strategy Analysis & Recommendation
  • 12.4.1. AbbVie Inc.
  • 12.4.2. AstraZeneca PLC
  • 12.4.3. F. Hoffmann-La Roche Ltd.
  • 12.4.4. Amgen Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adimab, LLC
• 3. Affimed GmbH
• 4. Alligator Bioscience AB
• 5. Amgen Inc.
• 6. Astellas Pharma Inc.
• 7. AstraZeneca PLC
• 8. Bristol-Myers Squibb
• 9. Eli Lilly and Company
• 10. Emergent BioSolutions Inc.
• 11. F. Hoffmann-La Roche Ltd.
• 12. Genmab A/S
• 13. Gilead Sciences, Inc.
• 14. Innovent Biologics, Inc.
• 15. Johnson & Johnson Services, Inc.
• 16. Merck KGaA
• 17. Mereo Biopharma Group PLC
• 18. Merus N.V.
• 19. Novartis AG
• 20. Pfizer Inc.
• 21. Pieris Pharmaceuticals, Inc.
• 22. Regeneron Pharmaceuticals Inc.
• 23. Sanofi S.A.
• 24. TG Therapeutics, Inc.
• 25. Xencor, Inc.